Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
a study on Solid Tumor
Solid Tumors PIK3CA PTEN TSC1/2 STK11 MTOR MYC MAPK advanced solid tumor advanced solid malignancies melanoma skin cancer ovarian cancer endometrium/uterus cancer bladder cancer cervical cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Squamous Cell Carcinoma, Squamous Cell Esophageal Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Neoplasms, Glandular and Epithelial Gastrointestinal Neoplasms Digestive System Neoplasms Head and Neck Neoplasms Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases 4EBP1 RMC-5552
Lead Scientists at UC Cancer
- Sai-Hong Ignatius Ou, MD (uci)
Health Sciences Professor, Medicine. Authored (or co-authored) 6 research publications.
- Jonathan Riess, MD (ucdavis)
Associate Professor, Hematology and Oncology. Authored (or co-authored) 74 research publications.
- Pamela Munster, MD (ucsf)
Professor, Medicine. Authored (or co-authored) 134 research publications.
- accepting new patients
- Start Date
- Completion Date
- Revolution Medicines, Inc.
- Phase 1
- Study Type
- Last Updated